Company intelligence / Profile preview

Pacific Edge

Dunedin, Otago, New Zealandpacificedgedx.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Pacific Edge’s Cxbladder suite of tests are commercially available and used for the detection, risk stratification, rule-out, and surveillance of urothelial bladder cancer. The products have demonstrated higher sensitivity than traditional cytology methods. The company has secured major US commercial agreements including with Kaiser Permanente and CMS/Medicare for reimbursement coverage[5]. Clinical adoption continues to expand internationally.

Therapeutic areas: OncologyNephrology
Modalities: Genomic biomarker testRNA assayProtein assay
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Cxbladder

Commercial

Indications: Bladder cancer

Partnerships

Kaiser PermanenteCenters for Medicare & Medicaid Services (CMS)United Healthcare Medicare Advantage Policy

Beyond the preview

Go deeper on Pacific Edge.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pacific Edge.

Explore the full profile